## CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs.

b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items.

Items with Roman numerals (i.. ii. iii. iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF\_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

\* Erforderlich

| Your name *   |   |
|---|---|
| First Last  |   |
| Nicolas Arnaud  |   |
| Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada University Medical Cente  |   |
| Your e-mail address * abc@gmail.com n.arnaud@uke.de   |   |
| Title of your manuscript * Provide the (draft) title of your manuscript.  |   |
| Effectiveness of a Web-Based Screening and Fully automated Brief Motivational Intervention for Adolescent Substance Use: A Randomized Controlled Trial  |   |
| Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status  | ne time you fill in this form)                              |
| $\bigcirc$ not submitted yet - in late draft status, just before submission   | on  |
| <ul> <li>submitted to a journal but not reviewed yet</li> </ul>   |   |
| <ul> <li>submitted to a journal and after receiving initial reviewer cor</li> </ul>   | nments  |
| O submitted to a journal and accepted, but not published yet  |   |
| ○ published   |   |
| O Sonstiges:  |   |
|   |   |
| Journal *  If you already know where you will submit this paper (or if it is al provide the journal name (if it is not JMIR, provide the journal na   |   |
| onot submitted yet / unclear where I will submit this   |   |
| <ul> <li>Journal of Medical Internet Research (JMIR)</li> </ul>   |   |
| ○ Sonstiges:  |   |
| Manuscript tracking number *  If this is a JMIR submission, please provide the manuscript tracking number can be found in the submission acknowledging as author in JMIR. If the paper is already published in JMIR is the four-digit number at the end of the DOI, to be found at the article in JMIR) | gement email, or when you<br>R, then the ms tracking number |
| $\bigcirc$ no ms number (yet) / not (yet) submitted to / published in JI  | MIR   |

| TITLE AND A  |  | . 1  |   |   |
|--|--|--|---|---|
| 1a) TITLE: Id  | entificati   | ion as   | a rand  | omized trial in the   |
| title  |  |  |   |   |
| 1a) Does your paper a<br>I.e does the title contair<br>under "other")  |  |  |   | ial"? (if not, explain the reason   |
| <ul><li>yes</li></ul>  |  |  |   |   |
| O Sonstiges:   |  |  |   |   |
| 1a-i) Identify the mod   | o of doliness:   | - لدنه ماه ه   |   |   |
| based" only if Interventi<br>"computer-based" or "el<br>context of "virtual reality<br>groups". Complement o | on includes non ectronic" only if (3-D worlds). r substitute pronart phone" inst | n-web-bas<br>f offline pi<br>Use "onlir<br>duct nam<br>tead of "ip | ed Internet co<br>roducts are us<br>ne" only in the<br>es with broad<br>hone"), espec | ", "interactive". Use "Internet-<br>mponents (e.g. email), use<br>ed. Use "virtual" only in the<br>context of "online support<br>er terms for the class of products<br>ially if the application runs on |
|  | 1 2  | 3 4  | 5   |   |
| subitem not at all impor   | tant 🔾 🔾 (   |  | essential   |   |
| this" to indicate direct q   | t sections from<br>uotes from you<br>ot in the ms, or<br>eening and Full         | manuscri<br>r manusc<br>briefly ex                                 | ript), or elabor<br>plain why the   | e quotes in quotation marks "like<br>ate on this item by providing<br>item is not applicable/relevant   |
|  |  |  |   | ~   |
| <b>1a-ii) Non-web-based</b> Mention non-web-based telephone support").                                       | -  | -  |   | ventions in title<br>tions in title, if any (e.g., "with  |
|  | 1 2  | 3 4  | 5   |   |
|  |  |  |   |   |

| LIAGE VALIF DADAF Addrage G   |  |   | -                        |                                 |                              |  |                        |
|---|--|---|--------------------------|---------------------------------|------------------------------|--|------------------------|
| Does your paper address s   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              | title (include quotes in quotation marks t), or elaborate on this item by providing  | 'like                  |
|   |  |   |                          |                                 |                              | ain why the item is not applicable/relevan   | nt                     |
| Not applicable: All compone   | onte i   | of th   | ο Int                    | orvo                            | ntior                        | a are purely   |                        |
| web-based.  | CIILS  | טו נוו  | e iiii                   | .ei ve                          | TILIOI                       | rare purery  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              | $\checkmark$   |                        |
|   |  |   |                          |                                 |                              |  |                        |
| 1a-iii) Primary condition o   | r tor  | aot   | arol                     | ın in                           | tho                          | title.   |                        |
| •   |  | _   | _                        | -                               |                              | e, if any (e.g., "for children with Type I   |                        |
|   | pased  | d and   | d Mo                     | bile                            | Inter                        | vention with Telephone Support for Child   | lren                   |
|   | 1  | 2   | 3                        | 4                               | 5                            |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
| subitem not at all important  | $\bigcirc$   | $\bigcirc$                                    | $\bigcirc$               | $\odot$                         | $\circ$                      | essential  |                        |
|   |  |   |                          |                                 |                              |  |                        |
| additional information not in for your study  | the r  | ns, c   |                          |                                 |                              | t), or elaborate on this item by providing ain why the item is not applicable/relevar  | nt                     |
| Yes, "Adolescent Substance  | e Us   | e"  |                          |                                 |                              | ^  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              | <b>~</b>   |                        |
|   |  |   |                          |                                 |                              |  |                        |
|   |  |   |                          |                                 |                              |  |                        |
| 41.)  | •  |   |                          |                                 |                              |  |                        |
| 1b) ABSTRACT:   | St   | ru  | ctı                      | ıre                             | d                            | summary of trial desig   | ın,                    |
| ,   |  |   |                          |                                 |                              | ,  | n,                     |
| methods, result   | S, a   | an  | d c                      | cor                             | ncl                          | usions   | n,                     |
| methods, result  NPT extension: Description   | <b>S, 6</b>  | an  | d c                      | cor                             | ncl                          | ,  | n,                     |
| methods, result NPT extension: Description centers, and blinding statu  | <b>S, 6</b> n of 6 s.  | an<br>expe                                    | d c                      | <b>CO</b> r<br>enta             | n <b>cl</b><br>I tre         | USIONS<br>atment, comparator, care providers,  |                        |
| methods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function   | S, 6   | an<br>expe                                    | d c                      | enta                            | n <b>cl</b><br>I tre         | usions   |                        |
| methods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function the METHODS section of the  | S, 6<br>n of e<br>s.<br>naliti   | an<br>expe<br>ies/                            | d com                    | enta<br>pon                     | ncl<br>I tre                 | USIONS atment, comparator, care providers, of the intervention and comparator i  | n                      |
| methods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function the METHODS section of t Mention key features/function abstract. If possible, also me   | S, an of each of s.  nalition he A conalite ention   | experies/ies/ies/in the                       | com<br>FRAC              | enta  pon cr pones s and        | ncl<br>I tre<br>ents<br>ents | usions atment, comparator, care providers,  of the intervention and comparator in the intervention and comparator in the inciples used for designing the site. Keep  | <b>n</b>               |
| methods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function the METHODS section of to Mention key features/function abstract. If possible, also me mind the needs of systemati  | S, an of es.  nalition he A constitution control of the constitution of the constituti | experies/ies/ies/ies/ies/ies/ies/ies/ies/ies/ | com<br>FRAC<br>comportes | enta  pon CT  pones s and nd in | ents                         | usions atment, comparator, care providers,  of the intervention and comparator in the intervention and comparator in the inciples used for designing the site. Keep ers by including important synonyms. (No | <b>n</b><br>in<br>ite: |
| nethods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function the METHODS section of to the Mention key features/function abstract. If possible, also mention the needs of systemation only report in the abstract will | S, 6 n of 6 s. naliti he A onalite entior c revi   | experies/enthe                                | comportes an ain p       | enta  pon CT  pones s and nd in | ents                         | usions atment, comparator, care providers,  of the intervention and comparator in the intervention and comparator in the inciples used for designing the site. Keep  | <b>n</b><br>in<br>ite: |
| methods, result NPT extension: Description centers, and blinding statu  1b-i) Key features/function the METHODS section of to Mention key features/function abstract. If possible, also me mind the needs of systemati  | S, 6 n of 6 s. naliti he A onalite entior c revi   | experies/enthe                                | comportes an ain p       | enta  pon CT  pones s and nd in | ents                         | usions atment, comparator, care providers,  of the intervention and comparator in the intervention and comparator in the inciples used for designing the site. Keep ers by including important synonyms. (No | <b>n</b><br>in<br>te:  |

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

| Does your paper address  | Subi   | rem  | 1111-1   |  |  |  |  |   |  |   |                        |
|--|--|--|--|--|--|--|--|---|--|---|------------------------|
| Copy and paste relevant sec<br>marks "like this" to indicate<br>providing additional informa<br>applicable/relevant for your   | ctions<br>direc  | fror<br>t quo<br>not ii  | n the  | e ma<br>from   | you  | r manuscrip  | t), or elab  | orate (   | on this  |   |                        |
| Only partly, due to word co<br>that "Participants were ran<br>motivational intervention g  | domi   | zed 1  | to a   | singl  | e se   | ssion brief  | ))".   |   |  |   |                        |
| <b>1b-ii) Level of human inve</b><br>Clarify the level of human in<br>vs. "therapist/nurse/care pr<br>providers involved, if any). (I  | volve<br>ovide<br>Note:  | men<br>r/ph<br>Only  | t in t<br>ysici<br>/ rep   | he al<br>an-a:<br>ort in   | bstra<br>ssist   | act, e.g., use<br>ted" (mentic<br>abstract wl  | e phrases<br>on number<br>nat the ma   | like "fu<br>and e<br>ain pap                                | ılly au<br>xperti  | tomated<br>se of  |                        |
| his information is missing f   |  |  |  |  |  | ext, conside   | er adding  | IT)   |  |   |                        |
|  | 1  | 2  | 3  | 4  | 5  |  |  |   |  |   |                        |
| subitem not at all important   | 0  | $\circ$  | $\circ$  | •  | 0  | essential  |  |   |  |   |                        |
| Copy and paste relevant sec<br>marks "like this" to indicate<br>providing additional informa   | ctions<br>direction<br>study   | fror<br>t quo<br>not in<br>y<br>y au   | n the<br>otes f<br>n the<br>toma   | e mai<br>from<br>ms,   | you<br>or b<br>web-  | r manuscrip<br>riefly explai<br>-based brief   | t), or elab<br>n why the   | orate (   | on this  |   |                        |
| Copy and paste relevant sec<br>marks "like this" to indicate<br>providing additional informa<br>applicable/relevant for your<br>No, but under "Objectives"   | ctions<br>direction<br>study   | fror<br>t quo<br>not in<br>y<br>y au   | n the<br>otes f<br>n the<br>toma   | e mai<br>from<br>ms,   | you<br>or b<br>web-  | r manuscrip<br>riefly explai<br>-based brief   | t), or elab<br>n why the   | orate (   | on this  |   |                        |
| Copy and paste relevant sec<br>marks "like this" to indicate<br>providing additional informa<br>applicable/relevant for your<br>No, but under "Objectives"   | ctions<br>direction<br>study   | fror<br>t quo<br>not in<br>y<br>y au   | n the<br>otes f<br>n the<br>toma   | e mai<br>from<br>ms,   | you<br>or b<br>web-  | r manuscrip<br>riefly explai<br>-based brief   | t), or elab<br>n why the   | orate (   | on this  |   |                        |
| motivational Intervention w  | etions<br>direction<br>study<br>': "full<br>vith no  | s from<br>t quo<br>not in<br>y<br>ly au<br>o fac   | tomate tomate to the tomate to | e mai<br>from<br>ms,<br>ated v   | you<br>or b<br>web-<br>con                                       | r manuscrip<br>riefly explai<br>-based brief<br>nponents ".  | t), or elab<br>n why the   | orate (   | on this  | s item b  | y                      |
| Copy and paste relevant sec<br>marks "like this" to indicate<br>providing additional informa<br>applicable/relevant for your<br>No, but under "Objectives"<br>motivational Intervention w  | eb-bathe / ere resonline ere woutcome trade ereson trade | aseconot in the control of the contr | If (see FRACE) ted (see FRACE) | e mai<br>from<br>ms,<br>ms,<br>ated v<br>face<br>CT<br>onlin<br>oup (o<br>to-fa<br>e sel<br>ifline<br>and<br>ndec<br>trials<br>ostra<br>y of t | web- con sses le vsclose ce c f-as: trial part d" or s usi cet w | r manuscripriefly explained based briefly explained based briefly explained based briefly exponents.  sement) vs.  offline), explained by the components of the components be sessed throw the components because the components becaus | face-to- g., from any p trial), ary (as part ough quest rial) (open any of the indicate of open any paper is | face an open d clariform the itionnai treatmeted the access | asses acce ify if the string in the string is entired; action in the string is entired; action in the string is entired; action in the string in the string in the string is entired; action in the string in the st | sments ss webs his was ention on s comm s a type being of blinc | s in site a for non of |
| Copy and paste relevant seconarks "like this" to indicate providing additional informate applicable/relevant for your.  No, but under "Objectives" motivational Intervention with the METHODS section of Mention how participants were from a clinic or a closed ourely web-based trial, or the assessment). Clearly say if an web-based trials). Note: In clinical trial in which both the administered. To avoid confinstead of "open", as "open" can self-enrol). (Note: Only in the control of the | eb-bathe / ere reconline ere woutcome trade ere restusion  | aseconot in the control of the contr | If (see FRACE) ted (see "blicker grower all of hers e "blicker gro | e mai<br>from<br>ms,<br>ms,<br>ated v<br>face<br>CT<br>onlin<br>oup (o<br>to-fa<br>e sel<br>ifline<br>and<br>ndec<br>trials<br>ostra<br>y of t | web- con sses le vsclose ce c f-as: trial part d" or s usi cet w | r manuscripriefly explained based briefly explained based briefly explained based briefly exponents.  sement) vs.  offline), explained by the components of the components be sessed throw the components because the components becaus | face-to- g., from any p trial), ary (as part ough quest rial) (open any of the indicate of open any paper is | face an open d clariform the itionnai treatmeted the access | asses acce ify if the string in the string is entired; action in the string is entired; action in the string is entired; action in the string in the string in the string is entired; action in the string in the st | sments ss webs his was ention on s comm s a type being of blinc | s in site a for non of |

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "In an open access purely web-based randomized controlled trial a convenience sample of adolescents aged 16 to 18 years from Sweden, Germany, Belgium and the Czech Republic was recruited using online and offline methods and screened online for at-risk substance use using the CRAFFT screening instrument. Participants were randomized to a single session brief motivational intervention group or an assessment-only control group but not blinded. Primary outcome was

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "2673 adolescents were screened and 1449 (54.2%) participants were randomized to the intervention or control group. 211 adolescents (14.5%) provided follow-up data after three months."

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 1b-v?

| Yes, "significant between-group effects for alcohol use indicate that targeted brief motivational intervention in a fully automated web-based format can be effective". | ^        |
|---|----------|
|   | <b>\</b> |

#### INTRODUCTION

## 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Early misuse of alcohol and other drugs is widespread in Europe with higher prevalence compared to other regions in the world such as the U.S. [1,2]. "

"The widespread use of alcohol and other drugs suggests that current capacities to prevent youth from initiating alcohol and other drug use are limited [15,16]. Prevention efforts should therefore target at-risk youth with indicated preventive

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

| 1 | 2 | 3 | 4 | 5 |           |
|---|---|---|---|---|-----------|
| 0 | 0 | 0 | 0 | • | essential |
|   |   |   |   |   | 1 2 3 4 5 |

Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Although previous studies that have proven the usefulness of web-based motivational interventions to address substance use and related problems mainly targeted emerging adults [35], the motivational methods that have been studied and found effective are relevant for constellations of risk factors in adolescence, such as their susceptibility to peer influences [36-39]. Motivational interventions are based on the therapeutic style and techniques put forward by Motivational Interviewing

# 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "The purpose of the present study was therefore to test the effectiveness of a fully automated web-based brief motivational intervention in a sample of at-risk substance using adolescents in four European countries. Our primary hypothesis was that participants in the intervention group would report significantly lower levels of past-month drinking (frequency, quantity, and frequency of binge drinking) at 3-month follow-up relative to baseline when compared to an

#### **METHODS**

# 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "A two-armed multi-site randomized control trial (RCT) design was applied"

# 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "No content or methodological modifications were made after trial commencement"

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The WISEteens intervention was pilot-tested" "open feedback, technical problems, translational ambiguities and other problems were documented and the program was adapted accordingly"

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

|   |   |  |  |  |  |  |  | <b>~</b>  |  |   |  |
|---|---|--|--|--|--|--|--|---|--|---|--|
| 4a-i) Computer / Internet<br>Computer / Internet literacy<br>explicitly clarified.  |   | -  | n im   | plici  | t "de  | facto"   | eligibili  | ty criter   | ion - th                                     | nis sho   | uld be   |
|   | 1   | 2  | 3  | 4  | 5  |  |  |   |  |   |  |
| subitem not at all important  | 0   | 0  | •  | 0  | 0  | essen  | ntial  |   |  |   |  |
|   |   |  |  |  |  |  |  |   |  |   |  |
| Does your paper address   |   |  |  |  |  |  |  |   |  |   |  |
| Copy and paste relevant sec<br>his" to indicate direct quote<br>additional information not in   | s fro   | m yc   | our m  | nanu   | scrip  | ot), or el   | laborate   | on this   | item   | by prov   | riding   |
| or your study Only implicitly, in the adole   | escen   | nt tar   | aet a  | ırour  | ) inte   | ernet ite  | eracv  |   |  |   |  |
| was presumed considered not explicitly addressed.   |   |  |  |  |  |  |  |   |  |   |  |
| not explicitly addressed.   |   |  |  |  |  |  |  |   |  |   |  |
|   |   |  |  |  |  |  |  |   |  |   |  |
|   |   |  |  |  |  |  |  |   |  |   |  |
|   |   |  |  |  |  |  |  | <b>~</b>  |  |   |  |
|   |   |  |  |  |  |  |  | <b>~</b>  |  |   |  |
| 4a-ii) Open vs. closed, we  | eb-ba   | nsed   | vs.  | face   | e-to-  | face a   | ssessn   | nents:  |  |   |  |
| Open vs. closed, web-based ecruited (online vs. offline), his was a purely web-based ntervention or for assessmen online-only trials, clarify if dentities was possible or w  | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hethe            | ace-t<br>from<br>, or t<br>i.e., t<br>icipa<br>er tec              | to-fan<br>n an<br>here<br>to wh<br>nts v                   | ce as<br>oper<br>were<br>at de<br>vere<br>cal or           | sses<br>a acc<br>e fac<br>egree<br>quas<br>r logi  | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical r                        | s: Menticebsite or<br>ce comp<br>ne study<br>nymous s<br>measure | on how<br>from a<br>conents<br>team to<br>and who             | clinic,<br>(as pa<br>knovether h             | and cl<br>art of tl<br>the pa<br>aving l                                      | arify if<br>ne<br>articipant.<br>multiple                                |
| Open vs. closed, web-based ecruited (online vs. offline), his was a purely web-based ntervention or for assessmen online-only trials, clarify if dentities was possible or w  | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hethe            | ace-1<br>from<br>, or t<br>i.e., t<br>icipa<br>er teo<br>used      | to-fan<br>n an<br>here<br>to wh<br>nts v                   | ce as<br>oper<br>were<br>lat de<br>vere<br>cal or<br>etect | sses<br>a acc<br>e fac<br>egree<br>quas<br>r logi  | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical r                        | s: Menticebsite or<br>ce comp<br>ne study<br>nymous s<br>measure | on how<br>from a<br>conents<br>team to<br>and who             | clinic,<br>(as pa<br>knovether h             | and cl<br>art of tl<br>the pa<br>aving l                                      | arify if<br>ne<br>articipant.<br>multiple                                |
| 4a-ii) Open vs. closed, we Open vs. closed, web-based recruited (online vs. offline), this was a purely web-based intervention or for assessment online-only trials, clarify if dentities was possible or we confirmation, phone calls) we subitem not at all important   | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hethe<br>vere u  | ace-from<br>, or t<br>i.e., t<br>icipa<br>er tec<br>used           | to-fan<br>n an<br>here<br>o wh<br>nts v<br>chnic<br>to de  | ce as<br>oper<br>were<br>nat do<br>were<br>cal or<br>etect | sses<br>n acc<br>e fac<br>egree<br>quas<br>r logi<br>t/pre   | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical r                        | s: Mention debsite or ce comple study aymous measure nese.       | on how<br>from a<br>conents<br>team to<br>and who             | clinic,<br>(as pa<br>knovether h             | and cl<br>art of tl<br>the pa<br>aving l                                      | arify if<br>ne<br>articipant.<br>multiple                                |
| Open vs. closed, web-based recruited (online vs. offline), this was a purely web-based ntervention or for assessmen online-only trials, clarify if dentities was possible or we confirmation, phone calls) w  | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hethe<br>vere u  | ace-from<br>, or t<br>i.e., t<br>icipa<br>er tec<br>used           | to-fan<br>n an<br>here<br>o wh<br>nts v<br>chnic<br>to de  | ce as<br>oper<br>were<br>nat do<br>were<br>cal or<br>etect | sses<br>n acc<br>e fac<br>egree<br>quas<br>r logi<br>t/pre   | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical revent th                | s: Mention debsite or ce comple study aymous measure nese.       | on how<br>from a<br>conents<br>team to<br>and who             | clinic,<br>(as pa<br>knovether h             | and cl<br>art of tl<br>the pa<br>aving l                                      | arify if<br>ne<br>articipant.<br>multiple                                |
| Open vs. closed, web-based recruited (online vs. offline), this was a purely web-based ntervention or for assessmen online-only trials, clarify if dentities was possible or we confirmation, phone calls) we subitem not at all important  | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hethe<br>vere u  | ace-1<br>from<br>, or t<br>i.e., t<br>icipa<br>er teo<br>used<br>2 | to-fan<br>n an<br>here<br>to wh<br>nts v<br>chnic<br>to de | ce as oper were lat do vere lat or etect                   | sses<br>n acc<br>e fac<br>egree<br>quas<br>r logi<br>t/pre   | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical revent th                | s: Mention debsite or ce comple study aymous measure nese.       | on how<br>from a<br>conents<br>team to<br>and who             | clinic,<br>(as pa<br>knovether h             | and cl<br>art of tl<br>the pa<br>aving l                                      | arify if<br>ne<br>articipant.<br>multiple                                |
| Open vs. closed, web-based recruited (online vs. offline), this was a purely web-based ntervention or for assessmentervention or for assessmentervention or for assessmentervention or for assessmentervention, clarify if dentities was possible or we confirmation, phone calls) we confirmation at all importanted books your paper address  | vs. fa<br>e.g.,<br>Il trial,<br>ent), i<br>parti<br>hethe<br>vere u | ace-i<br>from<br>, or t<br>i.e., t<br>icipa<br>er tece<br>2        | to-fan an here o wh nts v chnic to do                      | ce as oper were at devere cal or etect                     | ssess accepted factoring accepte | sments<br>cess we<br>ce-to-face<br>e got th<br>si-anon<br>istical r<br>event th            | s: Menticebsite or ce comple study symous measuremese.           | on how<br>from a<br>conents<br>team t<br>and whe<br>es (e.g., | clinic,<br>(as po<br>o knovether h<br>cookid | and cl<br>art of tl<br>v the pa<br>naving I                                   | arify if<br>ne<br>articipant<br>multiple<br>ail                          |
| Open vs. closed, web-based ecruited (online vs. offline), his was a purely web-based ntervention or for assessmentervention or for assessmentervention or for assessmentervention, placed or web confirmation, phone calls) we confirmation, phone calls) we confirmation at all important of the confirmation of | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hether<br>vere u | ace-1 from , or t i.e., t icipa er tecused 2                       | to-fan an here o wh nts v chnic to do 3                    | ce as oper were at devere cal or etect 4                   | ssess n acce face face face face face face face  | sments cess we ce-to-face e got th si-anon istical r event th  essen  cript (in ot), or el | s: Mention debsite or ce comple study aymous measured nese.      | on how from a conents team to and who as (e.g.,               | clinic, (as p. o knovether he cookie         | and cl<br>art of the<br>v the pa<br>naving n<br>es, ema<br>ation m<br>by prov | arify if<br>ne<br>articipant.<br>multiple<br>ail<br>arks "like<br>riding |
| Open vs. closed, web-based recruited (online vs. offline), his was a purely web-based ntervention or for assessmen online-only trials, clarify if dentities was possible or we confirmation, phone calls) we subitem not at all important   | vs. fa<br>e.g.,<br>I trial,<br>ent), i<br>parti<br>hether<br>vere u | ace-1 from , or t i.e., t icipa er tecused 2                       | to-fan an here o wh nts v chnic to do 3                    | ce as oper were at devere cal or etect 4                   | ssess n acce face face face face face face face  | sments cess we ce-to-face e got th si-anon istical r event th  essen  cript (in ot), or el | s: Mention debsite or ce comple study aymous measured nese.      | on how from a conents team to and who as (e.g.,               | clinic, (as p. o knovether he cookie         | and cl<br>art of the<br>v the pa<br>naving n<br>es, ema<br>ation m<br>by prov | arify if<br>ne<br>articipant.<br>multiple<br>ail<br>arks "like<br>riding |

Yes: "Five university research centres in Europe developed the purely web-based content of WISEteens Portal"

"We promoted the open-access WISEteens landing page to recruit a convenience sample of potential participants using both online and offline strategies. As offline strategies we developed print promotion materials (information leaflets and flyer cards) and distributed them in schools, youth-clubs, cafés,

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Those fulfilling the inclusion criteria then received study information including confidentiality, voluntariness of participation, and data security, as well as information about the randomization protocol."

## 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "All study measures were administered anonymously and online"

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

1 2 3 4 5

| his" to indicate direct quote   | ctions from the manuscript (include quotes in quotation marks "like<br>es from your manuscript), or elaborate on this item by providing<br>n the ms, or briefly explain why the item is not applicable/relevant  |
|---|--|
| or your study  Yes, "All study measures volline via self-reports at baand at follow-up (t1 3 mont with a valid email address. baseline assessment, partito participate in the follow- | were administered anonymously and asseline (t0 before randomization) aths after t0) and required registration at Three months after completing the ticipants, were automatically invited to assessment and guided by an email invitation with one reminder |
|   | ional affiliations are displayed iliations are displayed to potential participants [on ehealth media],   |
| s affiliations with prestigion  | bus hospitals or universities may affect volunteer rates, use, and intervention. (Not a required item – describe only if this may bias   |
|   | 1 2 3 4 5  |
| subitem not at all important  | t O O O essential  |
| dditional information not in<br>or your study<br>Yes, "It [the landing page]<br>study by highlighting confid  | described the main features of the identiality, content and source brief guided enrolment procedure  |
|   |  |
|   |  |
|   |  |
| 5) The intervent  | tions for each group with sufficient   |
| •   | tions for each group with sufficient replication, including how and when   |
| details to allow  | ·  |
| details to allow<br>they were actual<br>5-i) Mention names, credential, a<br>dention names, credential, a<br>duthors/evaluators are owner   | replication, including how and when  |
| details to allow<br>they were actua<br>5-i) Mention names, crede<br>Mention names, credential, a<br>authors/evaluators are owne   | replication, including how and when ally administered  lential, affiliations of the developers, sponsors, and owners affiliations of the developers, sponsors, and owners [6] (if hers or developer of the software, this needs to be declared in a        |

| this" to indicate direct qu  | ections from the manuscript (include quotes in quotation marks "libtes from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant   |
|--|--|
| the developing Team we throughout the Interver "The IT platform was end Hamburg."  "Competing interests  | f all affilated Research institutes and ere visible on the landing page and ion pages. rablished together with GAIA AG, ed in the development of the   |
| *  | ry/development process   |
|  | lopment process of the application and previous formative<br>oups, usability testing), as these will have an impact on adoption/u<br>reting results.   |
|  | 1 2 3 4 5  |
| 1.5  |  |
| Does your paper addre  | es subitem 5-ii?   |
| Does your paper addre<br>Copy and paste relevant<br>this" to indicate direct qu  |  |
| Does your paper address Copy and paste relevant this" to indicate direct quadditional information not for your study  "Five university research purely web-based cont 2011 and March 2012. together with GAIA AG Figure 2) was designed using visual material (emain features of the students)   | es subitem 5-ii? ections from the manuscript (include quotes in quotation marks "libtes from your manuscript), or elaborate on this item by providing  |
| Does your paper address Copy and paste relevant this" to indicate direct quadditional information not for your study  "Five university researd purely web-based cont 2011 and March 2012. together with GAIA AG Figure 2) was designed using visual material (emain features of the students)  | ections from the manuscript (include quotes in quotation marks "libtes from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant a centres in Europe developed the not of WISEteens portal between June The IT platform was established Hamburg. The landing page (see to create an appealing first impression g., pictures, video). It described the dy by highlighting confidentiality, ibility, and provided a brief guided   |
| Does your paper address Copy and paste relevant this" to indicate direct quadditional information not for your study  "Five university research purely web-based cont 2011 and March 2012. together with GAIA AG Figure 2) was designed using visual material (emain features of the student and source crees.  5-iii) Revisions and up Revisions and updating. application/intervention intervention underwent redevelopment and/or contraction.              | ections from the manuscript (include quotes in quotation marks "librates from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant a centres in Europe developed the not of WISEteens portal between June The IT platform was established Hamburg. The landing page (see to create an appealing first impression g., pictures, video). It described the dy by highlighting confidentiality, ibility, and provided a brief guided a brief guided a brief guided a brief guided and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the ent was "frozen" during the trial. Describe dynamic components suggested to the distribution of the replicability of the |
| Does your paper addres Copy and paste relevant this" to indicate direct quadditional information not for your study  "Five university researd purely web-based cont 2011 and March 2012. together with GAIA AG Figure 2) was designed using visual material (emain features of the stucontent and source cre  5-iii) Revisions and up Revisions and updating. application/intervention intervention underwent redevelopment and/or con as news feeds or changi | ections from the manuscript (include quotes in quotation marks "librates from your manuscript), or elaborate on this item by providing in the ms, or briefly explain why the item is not applicable/relevant a centres in Europe developed the not of WISEteens portal between June The IT platform was established Hamburg. The landing page (see to create an appealing first impression g., pictures, video). It described the dy by highlighting confidentiality, ibility, and provided a brief guided a brief guided a brief guided a brief guided and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the and comparator, if applicable) evaluated, or describe whether the ent was "frozen" during the trial. Describe dynamic components suggested to the distribution of the replicability of the |

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing

| Yes, there were no major i   | modif                                       | ficati                    | ons                            | durir  | ıg Tr                                 | ial.  |  |  |  |                                   |                                   |   |              |
|--|---|---------------------------|--------------------------------|--|---------------------------------------|---|--|--|--|-----------------------------------|-----------------------------------|---|--------------|
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  | ~  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
| 5-iv) Quality assurance m  | etho  | ds                        |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
| Provide information on qual  | ity as                                      | ssura                     |                                | met  | nods                                  | to ensur  | e acc  | uracy  | and  | qua                               | lity o                            | f   |              |
| information provided [1], if a   | pplic                                       | able                      | <u>.</u>                       |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  | 1   | 2                         | 3                              | 4  | 5                                     |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   | _  |  |  |                                   |                                   |   |              |
| subitem not at all important   | $\bigcirc$                                  | $\circ$                   | $\circ$                        | $\circ$  | $\odot$                               | essentia  | al   |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
|  |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
| Does your paper address  | subi  | tem                       | 5-iv                           | ?  |                                       |   |  |  |  |                                   |                                   |   |              |
| Copy and paste relevant sec  | ctions                                      | s fro                     | m th                           | e ma   | nus                                   | cript (incl   | ude q  | uotes  | in q   | uota                              | tion                              | marks                                     | "like        |
| this" to indicate direct quote   | s fro                                       | m yo                      | our n                          | nanu   | scrip                                 | t), or ela  | borate   | e on tl  | his it   | em l                              | oy pr                             | ovidin                                    | g            |
| additional information not ir  | 1 the                                       | ms,                       | or br                          | iefly  | expl                                  | ain why t   | he ite   | m is r   | not a  | pplic                             | cable                             | /relev                                    | ant          |
| for your study   |   |                           |                                |  |                                       |   |  |  |  |                                   |                                   |   |              |
| Yes, all Content and imple empirically grounded and  |   |                           |                                | s the  | oret                                  | ically and  | I  | ^  |  |                                   |                                   |   |              |
|  |   |                           |                                | s the  | oret                                  | ically and  | I  | ^  |  |                                   |                                   |   |              |
|  |   |                           |                                | s the  | eoret                                 | ically and  | I  |  |  |                                   |                                   |   |              |
|  |   |                           |                                | s the  | eoret                                 | ically and  | l  | <  |  |                                   |                                   |   |              |
| empirically grounded and   | ore-te                                      | estec                     | d.                             |  |                                       |   |  | <  |  |                                   |                                   |   |              |
| empirically grounded and particular services services and particular services services and particular services  | ore-te                                      | blis                      | d.<br>hing                     | the  | sou                                   | rce code  | e, and   | _  |  | _                                 |                                   |   |              |
| empirically grounded and personal section of the se | oy pu<br>ure v                              | blis                      | hing<br>o, an                  | the  | sou<br>pro                            | rce code  | e, and   | arts   | of th  | ne al                             | gori                              |   | used         |
| 5-v) Ensure replicability b screenshots/screen-capt Ensure replicability by publis   | oy pu<br>ure v                              | blislyided                | hing<br>o, an                  | the  | sou<br>pro                            | rce code<br>viding fl<br>and/or p                         | e, and<br>owch                                 | narts<br>ng sci  | <b>of th</b><br>reen   | <b>re al</b><br>shot              | <b>gori</b><br>s/sc               | reen-                                     |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provided   | oy pu<br>ure v<br>shing<br>ling f           | blislyided                | hing<br>o, an<br>sour          | the  | sou<br>pro<br>ode,<br>the a           | rce code<br>viding fl<br>and/or p                         | e, and<br>owch<br>rovidir<br>s used            | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability by screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi   | oy pu<br>ure v<br>shing<br>ling f           | blislyided                | hing<br>o, an<br>sour          | the  | sou<br>pro<br>ode,<br>the a           | rce code<br>viding fl<br>and/or p                         | e, and<br>owch<br>rovidir<br>s used            | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability by screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi   | oy pu<br>ure v<br>shing<br>ling f           | blis video the lowo       | hing<br>o, an<br>sour<br>chart | the ad/orce cos of repli   | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p                         | e, and<br>owch<br>rovidir<br>s used            | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability by screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi   | oy pu<br>ure v<br>shing<br>ling f           | blis video the lowo       | hing<br>o, an<br>sour          | the ad/orce cos of repli   | sou<br>pro<br>ode,<br>the a           | rce code<br>viding fl<br>and/or p                         | e, and<br>owch<br>rovidir<br>s used            | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princit reporting.   | oy pu<br>ure v<br>shing<br>ling f<br>ple b  | blish rideo the lowce ab  | hing<br>o, an<br>sour<br>chart | the id/or ce cos of replied  | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p<br>lgorithm<br>the stud | e, and<br>owch<br>rovidir<br>s used<br>y) is a | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princit reporting.   | oy pu<br>ure v<br>shing<br>ling f<br>ple b  | blish rideo the lowce ab  | hing<br>o, an<br>sour<br>chart | the ad/orce cos of repli   | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p                         | e, and<br>owch<br>rovidir<br>s used<br>y) is a | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princit reporting.   | oy pu<br>ure v<br>shing<br>ling f<br>ple b  | blish rideo the lowce ab  | hing<br>o, an<br>sour<br>chart | the id/or ce cos of replied  | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p<br>lgorithm<br>the stud | e, and<br>owch<br>rovidir<br>s used<br>y) is a | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi reporting.  | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish the lowce ab        | hingo, an sourchart le to      | the ad/or ce cos of replied 4  | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p<br>lgorithm<br>the stud | e, and<br>owch<br>rovidir<br>s used<br>y) is a | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princit reporting.   | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish the lowce ab        | hingo, an sourchart le to      | the ad/or ce cos of replied 4  | sou<br>• pro<br>ode,<br>the a<br>cate | rce code<br>viding fl<br>and/or p<br>lgorithm<br>the stud | e, and<br>owch<br>rovidir<br>s used<br>y) is a | n <b>arts</b><br>ng sci<br>d. Rep                        | <b>of th</b><br>reen<br>olical   | <b>ne al</b><br>shot<br>bility    | gori<br>s/sc<br>(i.e.,            | reen-<br>other                            |              |
| 5-v) Ensure replicability by screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi reporting.  Subitem not at all important poes your paper address copy and paste relevant see  | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish rideo the lowce ab  | hingo, an sour shart le to     | the ad/or ce c s of replii   | sou<br>proode,<br>the acate           | rce code viding fl and/or p llgorithm the stud essentia   | e, and<br>owch<br>rovidir<br>s used<br>y) is a | uarts<br>ng sci<br>d. Rep<br>n halln                     | of the reen of the | ne all<br>shot<br>oility<br>of so | gori<br>s/sc/<br>(i.e.,<br>cient  | reen-<br>other<br>ific<br>marks           | : "like      |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi reporting.  Does your paper address Copy and paste relevant sections to indicate direct quote   | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish video the lowore ab | hingo, an sour shart le to     | the ad/or ce constant of the c | sou<br>proode,<br>the acate           | rce code viding fl and/or p llgorithm the stud  essentia  | e, and owch roviding sused by) is a            | uarts<br>ng sci<br>d. Rep<br>n halln<br>uotes<br>e on tl | of the reen blical nark in q   | ne all shot of solutions and uota | gori<br>s/sci<br>(i.e.,<br>ccient | reen-<br>other<br>ific<br>marks<br>ovidin | ; "like<br>g |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi reporting.  Does your paper address Copy and paste relevant sections to indicate direct quote additional information not in   | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish video the lowore ab | hingo, an sour shart le to     | the ad/or ce constant of the c | sou<br>proode,<br>the acate           | rce code viding fl and/or p llgorithm the stud  essentia  | e, and owch roviding sused by) is a            | uarts<br>ng sci<br>d. Rep<br>n halln<br>uotes<br>e on tl | of the reen blical nark in q   | ne all shot of solutions and uota | gori<br>s/sci<br>(i.e.,<br>ccient | reen-<br>other<br>ific<br>marks<br>ovidin | ; "like<br>g |
|  | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish video the lowore ab | hingo, an sour shart le to     | the ad/or ce constant of the c | sou<br>proode,<br>the acate           | rce code viding fl and/or p llgorithm the stud  essentia  | e, and owch roviding sused by) is a            | uarts<br>ng sci<br>d. Rep<br>n halln<br>uotes<br>e on tl | of the reen blical nark in q   | ne all shot of solutions and uota | gori<br>s/sci<br>(i.e.,<br>ccient | reen-<br>other<br>ific<br>marks<br>ovidin | ; "like<br>g |
| 5-v) Ensure replicability be screenshots/screen-capt Ensure replicability by public capture video, and/or provide researchers should in princi reporting.  Does your paper address Copy and paste relevant sections to indicate direct quote additional information not in   | by pu<br>ure v<br>shing<br>ling f<br>ple be | blish video the lowore ab | hingo, an sour shart le to     | the ad/or ce constant of the c | sou<br>proode,<br>the acate           | rce code viding fl and/or p llgorithm the stud  essentia  | e, and owch roviding sused by) is a            | uarts<br>ng sci<br>d. Rep<br>n halln<br>uotes<br>e on tl | of the reen blical nark in q   | ne all shot of solutions and uota | gori<br>s/sci<br>(i.e.,<br>ccient | reen-<br>other<br>ific<br>marks<br>ovidin | ; "like<br>g |

| Yes, "The trial design was<br>Selected sceenshots are in   |  | uscript.   | ^   |
|--|--|--|---|
|  |  |  |   |
|  |  |  | ~   |
| 5-vi) Digital preservation   |  |  |   |
| Digital preservation: Provide change or disappear over the change or disappear over the change of th | ne course of the year<br>on.org, and/or publinges behind login so  | ars; also make sure<br>shing the source co<br>creens cannot be a | the intervention is archived ode or screenshots/videos  |
|  | 1 2 3 4  | 5  |   |
| subitem not at all important   |  | essential  |   |
| his" to indicate direct quote  | es from your manus   | script), or elaborate  | on this item by providing   |
| his" to indicate direct quote  | es from your manus   | script), or elaborate  |   |
| additional information not in<br>or your study   | 1 the ms, or briefly   | explain why the iter   | m is not applicable/relevant  |
| Only limited, availibility of study period, untill further is not accessible.  A full set of screenshots ca (NA, CB) on request.   | funding can be obta  | ained the Website  |   |
| (NA, OB) on request.   |  |  |   |
|  |  |  |   |
| 5-vii) Access  |  |  |   |
| describe how participants o<br>for editors/reviewers/reade   | not, whether they he<br>btained "access to<br>rs, consider to prov | nad to be a membe<br>the platform and Ir<br>ride a "backdoor" lo | hat setting/context, if they<br>r of specific group. If known,<br>nternet" [1]. To ensure access<br>gin account or demo mode<br>or archiving purposes, see vi). |
|  | 1 2 3 4  | 5  |   |
| subitem not at all important   |  | essential  |   |
|  |  |  |   |
| Does your paper address  |  | nuscrint (include a  | uotes in quotation marks "like  |
| this" to indicate direct quote   | es from your manus   | script), or elaborate  |   |

### https://docs.google.com/forms/d/1KlxFl4iTrxRIWADX-jCukJwHv4lE5IPjlPdqyWTz... 17.09.2015

Yes, open access, no costs involved and no membership to any specific group besides the age group (16-18 years) was required.

"three-fold online recruitment strategy with high rank of our websites' domain in widely used search engines, advertisements via popular social media and links on affiliated health promotion sites."

## 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

|                              | ı | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |

#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "The IT platform was established together with GAIA AG, Hamburg. The landing page (see Figure 2) was designed to create an appealing first impression using visual material (e.g., pictures, video). It described the main features of the study by highlighting confidentiality, content and source credibility, and provided a brief guided enrolment procedure [51]. Key to developing the content was the integration of MI principles and techniques in a single session together with an open-access

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | • | 0 | essential |

#### Does your paper address subitem 5-ix?

WISEteens was a single session "one-stop-shopping" motivational Intervention that encouraged reduced substance use and attainment of self-selected behavioral Goals. regarding Intervention use: "Participants in the intervention condition received a log-in

code to enable exit and re-entrance. "

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

1 2 3 4 5 subitem not at all important ( ) ( ) ( ) essential

#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "purely web-based randomized controlled trial" "fully automated web-based brief motivational intervention with no personal involvement"

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 generalizability).

1 2 3 4 5 subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-xi? \*

No prompts/reminders except for Trial/ follow up assessment: "Three months after completing the baseline assessment, participants, were automatically invited to participate in the follow-up assessment and guided by an integrated hyperlink in the email invitation with one reminder email after 1 week."

#### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable

## 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Substance use: All outcome measures concerned use in the past 30 days. Change in alcohol use (frequency, frequency of binge drinking and quantity) between the two assessments was the primary outcome and measured based on the three items of the AUDIT-C screening tool [61]. This measure provides a widely used and valid index sumscore for problem alcohol use of adolescents [63]. The three indicators are drinking frequency ("How often did you have a drink containing


| CHERRIES items to descri  | be h                                      | ow 1                              | the o                                   | ques                            | tion                           | vere validated for online use and apply nnaires were designed/deployed   |
|---|---|-----------------------------------|---|---------------------------------|--------------------------------|--|
|   |   |                                   |   |                                 |                                | nnaires, describe if they were validated for how the questionnaires were |
|   | 1   | 2                                 | 3                                       | 4                               | 5                              |  |
| subitem not at all important  | 0   | 0                                 | •                                       | 0                               | 0                              | essential  |
| Does your paper address   |   |                                   |   |                                 |                                |  |
| Copy and paste relevant sec<br>Limited, to our knowledge s  |   |                                   |   |                                 |                                |  |
| validated for online use.   |   |                                   |   |                                 |                                |  |
| 6a-ii) Describe whether ar<br>defined/measured/monito   |   | ow "                              | use'                                    | ' (inc                          | cludi                          | ing intensity of use/dosage) was   |
| Describe whether and how "idefined/measured/monitore important process outcomes   | d (lo                                     | gins                              | , logi                                  | file a                          | naly                           | rsis, etc.). Use/adoption metrics are                                    |
|   | 1   | 2                                 | 3                                       | 4                               | 5                              |  |
| subitem not at all important  | 0   | 0                                 | 0                                       | •                               | 0                              | essential  |
| Does your paper address sometimes of Copy and paste relevant section Yes, logins were document who collected and provided collaboration (Hamburg) "In the intervention group, I intervention as measured by page of the intervention ha | tions<br>ted b<br>d all o<br>N=45<br>by a | oy the<br>data<br>53 (6<br>log fi | m ma<br>e sub<br>to th<br>3.4%<br>le re | anus<br>oconi<br>ne PI<br>%) co | tract<br>of the<br>mple<br>whe | ting Partner the Research eted the brief ether the last                  |
| obtained  |   |                                   |   |                                 |                                | tative feedback from participants was                                    |
| through emails, feedback for  |   | inter                             |   | s, fo                           |                                |  |
| subitem not at all important  |   |                                   |   |                                 |                                | essential  |
| Does your paper address so  | subi                                      | tem                               | 6a-i                                    | iii?                            |                                |  |

Only partly and in the pre-test with no qualitative Feedback during the main Evaluation.
"Furthermore, open feedback, technical problems, translational ambiguities and other problems were documented"

## 6b) Any changes to trial outcomes after the trial commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

## 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Sample size calculation was based on the primary outcome with regard to effect sizes for alcohol use revealed by a recent review on web-based interventions for young people [31]. According to results from similar studies we expected a small effect size (Cohen's d=0.2). To reach power of 80% at a type I error rate of 5% in a two-sided test and expecting a dropout

rate of approximately 50% [27,62] we aimed at N=400 per

# 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| or your orday   |   |
|-----------------|---|
| Not applicable. |   |
|                 |   |
|                 |   |
|                 |   |
|                 |   |
|                 |   |
|                 |   |
|                 |   |
|                 |   |
|                 | • |
|                 |   |

# 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| Yes, "Randomization was generated automatically by an online computer program without stratification." |  |
|--|--|
|  |  |
|  |  |

# 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

| No restriction on randomisation.  "The envisioned number of participants was sufficient to ensure randomization integrity and a likely balanced distribution among the two parallel groups" | ^        |
|---|----------|
|   | <b>\</b> |

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| Yes, "Participants were not blinded to random allocation" | ^ |
|---|---|
|   |   |
|   | > |

# 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| Yes, "Randomization was generated automatically by an online computer program without stratification." |
|--|
|  |

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5

| subitem not at all importa  | ant (   | 0 0                        | ) •             | 0                | essential                 |  |                                    |                       |                                   |
|---|---|----------------------------|-----------------|------------------|---------------------------|--|------------------------------------|-----------------------|-----------------------------------|
| Does your paper addre Copy and paste relevant s this" to indicate direct qu additional information no | sections<br>otes fror                         | from t<br>n your           | he ma<br>manu   | anusc<br>Iscrip  | :), or elaboi             | ate on                                     | this iter                          | n by pro              | viding                            |
| for your study Yes, "Participants were Due to "no contact " bet during the study Resea                | tween Re                                      | esearcl                    | hers a          | and pa           |                           | ^  |                                    |                       |                                   |
| 11a-ii) Discuss e.g., wh<br>'intervention of interes  |   |                            |                 |                  |                           |  | ion was                            | s the                 |                                   |
| vhether participants kne  | w which                                       | -ii) can<br>interve        | creat<br>ention | te bias<br>was t | ses and ce                | tain ex                                    |                                    |                       |                                   |
| whether participants kne  | w which                                       | -ii) can                   | creat<br>ention | te bias<br>was t | ses and ce                | tain ex                                    |                                    |                       |                                   |
| Informed consent proced whether participants knewas the "comparator".  Subitem not at all importa     | w which                                       | -ii) can<br>interve<br>2 3 | creatention     | te bia:<br>was t | ses and ce<br>he "interve | tain ex                                    |                                    |                       |                                   |
| whether participants knewas the "comparator".   | w which  1  ant   ss subit sections otes from | em 11 from t               | a-ii?           | 5 Onnuscription  | essential                 | rtain ex<br>ntion of<br>e quote<br>rate on | f interes<br>s in quo<br>this iter | otation r<br>n by pro | vhich on<br>marks "lik<br>oviding |

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

| N | ot applicable. | <b>\</b>    |
|---|----------------|-------------|
|   |                |             |
|   |                | <b>&gt;</b> |

## 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes specified in Statistical analyses:

"We first analysed data on sample characteristics using t-tests (for metric data) and X2-tests (for categorical data) to test for differences between intervention conditions. Next we performed logistic regressions with completers (i.e., those who provided valid follow-up data) vs. drop-outs as the binary dependent variable to test for possible attrition bias using all available sociodemographic and substance use variables as

#### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |

#### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### Yes:

All analyses are based on a complete-case data set and an intention-to-treat (ITT) sample with imputation of missing followup data based on Expectation Maximization (EM). Both results are relevant and commonly reported in web-based interventions particularly when drop-out is large [71]. EM is a single imputation method that was shown to outperform the multiple imputation module available in SPSS in eHealth

# 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

#### Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| ior your orday  |   |
|-----------------|---|
| Not applicable. | ^ |
|                 |   |
|                 |   |
|                 |   |
|                 | ~ |

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

#### X26-i) Comment on ethics committee approval

|                              | 1 | 2 | 3 | 4 | 5 |          |
|------------------------------|---|---|---|---|---|----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essentia |
|                              |   |   |   |   |   |          |

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Ethical approval was granted by the responsible Ethics Committees in all participating countries (Chamber of Physicians Hamburg (Germany), Prague Psychiatric Centre (Czech Republic), University Hospital of Antwerp and the University of Antwerp (Belgium), and the Regional Ethics Board in Stockholm (Sweden))"

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |

#### Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Those fulfilling the inclusion criteria then received study information including confidentiality, voluntariness of participation, and data security, as well as information about the randomization protocol."

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

|                              | 1          | 2          | 3          | 4 | 5          |          |
|------------------------------|------------|------------|------------|---|------------|----------|
| subitem not at all important | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | • | $\bigcirc$ | essentia |

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The participants were anonymous throughout the study. At the first visit they were asked for registration which required a user name, e-mail address and a password that did not contain their name."

### **RESULTS**

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Yes: "2673 participants logged on the WISEteens web-portal and participated in the initial screening. 655 (24.5%) were excluded from the study due to a negative CRAFFT screening. This resulted in 2018 (75.5%) adolescents who gave consent to participate in the study and started subsequent baseline assessment (t0). A total of 569 (28.1%) dropped out during the baseline assessment leaving 1449 participants who completed baseline assessment and were randomized to either the

# 13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| - <b>, ,</b>                        |   |
|-------------------------------------|---|
| Yes, see study flow chart Figure 1. | ^ |
|                                     |   |
|                                     |   |
|                                     | ~ |

#### 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

1 2 3 4 5
subitem not at all important \( \) \( \) \( \) \( \) \( \) essential

#### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| item is not applicable, relevant is year etaal |   |
|--|---|
| Yes, see study flow chart Figure 1.            | ^ |
|  |   |
|  |   |
|  | ~ |

# 14a) Dates defining the periods of recruitment and follow-up


| Does your paper address (       | CON        | SOF        | RT su      | ubite   | em 1      | 4a? *             |                                   |
|---------------------------------|------------|------------|------------|---------|-----------|-------------------|-----------------------------------|
|                                 |            |            |            |         |           |                   | quotes in quotation marks "like   |
| this" to indicate direct quotes |            |            |            |         |           |                   |                                   |
| additional information not in   | the        | ms,        | or br      | iefly   | expl      | ain why the it    | tem is not applicable/relevant    |
| or your study                   |            |            |            |         |           |                   |                                   |
| Yes, "The web portal was s      | imul       | ltane      | ouel       | v lai   | ınch      | ed in all four    |                                   |
| countries in June 2012 with     |            |            |            |         |           |                   |                                   |
| Countries in ourie 2012 with    | 1100       | ıuı        | iciit      | LIII IV | arcii     | 2010 .            |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            | _          |            |         |           |                   |                                   |
| 4a-i) Indicate if critical "s   | secu       | ılar e     | even       | ts" i   | fell i    | nto the stud      | ly period                         |
| ndicate if critical "secular ev | ents       | " fel      | linto      | the     | stuc      | ly period, e.g.   | , significant changes in Internet |
| esources available or "chan     | ges i      | in co      | mpu        | ter h   | ardv      | vare or Intern    | net delivery resources"           |
|                                 |            |            |            |         |           |                   | •                                 |
|                                 | 1          | 2          | 3          | 4       | 5         |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
| subitem not at all important    | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\odot$ | $\circ$   | essential         |                                   |
|                                 |            |            |            |         |           |                   |                                   |
| or your study  Not applicable   |            |            |            |         |           |                   |                                   |
| . тот арриоасто                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   | <b>V</b>                          |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
|                                 |            |            |            |         |           |                   |                                   |
| 14b) Why the tri                | ial        | ρr         | nde        | Ы       | $\circ$ r | was st            | onned (early)                     |
| Tab) willy the th               | ıaı        | CI         | iuc        | ,u      | Oi        | was st            | opped (carry)                     |
|                                 |            |            |            |         |           |                   |                                   |
| oes your paper address (        | CON        | SOF        | RT sı      | ubite   | em 1      | 4b? *             |                                   |
|                                 |            |            |            |         |           |                   | quotes in quotation marks "like   |
|                                 |            |            |            |         |           |                   | ate on this item by providing     |
| idditional information not in   |            |            |            |         |           |                   |                                   |
|                                 | trie       | 1115,      | וט וט      | епу     | expi      | alli willy the it |                                   |
| or your study                   |            |            |            |         |           |                   | tern is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |
| Not applicable.                 |            |            |            |         |           |                   | term is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | em is not applicable/relevant     |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |
|                                 |            |            |            |         |           |                   | tern is not applicable/relevant   |

## 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



#### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: provided in tables 2a and 2b, and in text: "In the randomized sample (intention-to-treat population) the mean age was 16.8 years (SD=0.74), 48.2% of the participants were women and 97.2% were currently attending school. Most participants were recruited in the Czech Republic (62.8%) due to a more intense offline recruitment in this country indicating that adjustment of country of residence as an additional covariate was required in subsequent analyses. Participants in

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions


Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the

| numbers per group). Alv  | 1  | 0  | 0   | Λ  | _  |  |   |   |
|--|--|--|---|--|--|--|---|---|
|  | ı  | -2   | 3   | 4  | 5  |  |   |   |
| subitem not at all impor   | rtant 🔘  | 0  | 0   | •  | 0  | essenti  | al  |   |
| Does your paper addr   | ooo oubi   | tom  | 16 i  | <b>2</b> *                                 |  |  |   |   |
| Copy and paste relevan<br>this" to indicate direct q   | t sections<br>uotes fro  | fror<br>m yo                                     | n the   | mai<br>anus                                | scrip  | t), or ela   | borate  | uotes in quotation marks "like on this item by providing m is not applicable/relevant     |
| Yes, both non-imputed<br>Attrition and interventi<br>analyzed for<br>possible bias.  |  |  |   |  |  |  |   |   |
|  |  |  |   |  |  |  |   |   |
|  |  |  |   |  |  |  |   | ~   |
| 44 ") D :  |  |  |   |  |  |  |   | ~   |
| <b>16-ii) Primary analysi</b><br>Primary analysis should   |  |  |   |  |  |  | ses co  | uld include comparing only  |
| Primary analysis should  | d be intent  | t-to-t   | reat,   | seco                                       | onda   | ry analys  |   | uld include comparing only omized sample (see 18-i).                                      |
| Primary analysis should  | l be intent<br>oriate cave   | t-to-t<br>eats                                   | reat,   | secc<br>this i                             | onda   | ry analys  |   |   |
| Primary analysis should  | d be intent<br>priate cave   | t-to-t<br>eats<br>2                              | reat,<br>that   | seco<br>this i<br>4                        | onda<br>is no<br>5                                     | ry analys  | a rando   |   |
| Primary analysis should<br>"users", with the approp  | d be intent<br>priate cave   | t-to-t<br>eats<br>2                              | reat,<br>that   | seco<br>this i<br>4                        | onda<br>is no<br>5                                     | ry analys<br>longer a  | a rando   |   |
| Primary analysis should<br>"users", with the approp  | I be intent<br>oriate cave<br>1  | eats   | reat,<br>that   | seconthis i                                | onda<br>is no<br>5                                     | ry analys<br>longer a  | a rando   |   |
| Primary analysis should users", with the appropriate subitem not at all importance of the sould be subited as a subitem of the subitem not at all importance of | be intent<br>priate cave<br>1<br>rtant O   | t-to-teats                                       | reat, that  | seconthis i                                | onda<br>s no<br>5                                      | ry analys<br>longer a<br>essenti   | a rando<br>al                                       |   |
| Primary analysis should "users", with the appropriate subitem not at all importance of the state | t sections uotes from  | tem s from you                                   | 3  16-i  n the  | secothis i  4  •  i?  e manus              | s no<br>5  | essenti  | a rando<br>al<br>al<br>ude qu                       | omized sample (see 18-i).   |
| Primary analysis should users", with the appropriate subitem not at all important properties. Properties and paste relevant this to indicate direct quadditional information refor your study.   | t sections until the first the sections until the sections until the sections the section the sections the section the sections the sections the sections the section the sections the section the section the sections the section that the section the section the section | t-to-t<br>2<br>2<br>ttem<br>frorm yours, (       | 16-i m the  | this i  4  • main anus efly                | 5 Onuscessoripe explain                                | essenti<br>eript (incl<br>t), or ela   | a rando<br>al<br>lude qu<br>borate                  | omized sample (see 18-i).<br>uotes in quotation marks "lik<br>e on this item by providing |
| Primary analysis should users", with the appropriate subitem not at all important and paste relevant this to indicate direct quaditional information refor your study  Yes, "All analyses are an intention-to-treat (I' follow-up data based or results are relevant ar  | t sections uotes from Expect of Common E | tem  tem  from your a colle with action only re- | reat, that 3  16-i  16-i  n the or bri  ompl th im  Ma. repor | 4  • mail anus efly ete-coputa ximiz ted i | nusc<br>scrip<br>explacase<br>tition<br>zation<br>n we | essenti<br>essenti<br>essenti<br>estipt (incl<br>t), or ela<br>ain why t<br>data set<br>of missii<br>n (EM). I | lude que borate the iter the iter the iter the both | omized sample (see 18-i).<br>uotes in quotation marks "lik<br>e on this item by providing |
| Primary analysis should users", with the appropriate subitem not at all important and paste relevant this to indicate direct quaditional information refor your study  Yes, "All analyses are an intention-to-treat (I' follow-up data based of the state of | t sections uotes from Expect of Common E | tem  tem  from your a colle with action only re- | reat, that 3  16-i  16-i  n the or bri  ompl th im  Ma. repor | 4  • mail anus efly ete-coputa ximiz ted i | nusc<br>scrip<br>explacase<br>tition<br>zation<br>n we | essenti<br>essenti<br>essenti<br>estipt (incl<br>t), or ela<br>ain why t<br>data set<br>of missii<br>n (EM). I | lude que borate the iter the iter the iter the both | omized sample (see 18-i).<br>uotes in quotation marks "lik<br>e on this item by providing |

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing



# 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

#### Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

| ioi your olday  |   |
|-----------------|---|
| Not applicable. | ^ |
|                 |   |
|                 |   |
|                 | ~ |

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

|                              | I | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | • | essential |

#### Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "All analyses are based on a complete-case data set and an intention-to-treat (ITT) sample with imputation of missing follow-up data"

# 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

#### Does your paper address CONSORT subitem 19? \*

|   |                            |  |  |                       |  |   | 1  |                             |                                     |  |          |
|---|----------------------------|--|--|-----------------------|--|---|--|-----------------------------|-------------------------------------|--|----------|
|   |                            |  |  |                       |  |   |  |                             |                                     |  |          |
| 19-i) Include privacy bread   | ches                       | , tec  | chnic  | cal p                 | robl   | lems  |  |                             |                                     |  |          |
| nclude privacy breaches, tec<br>participants, but also inciden<br>problems, and other unexpec<br>unintended positive effects [  | its si                     | uch a  | as pe  | erceiv                | ved o  | or real priva   | acy bre  | aches [1                    | ], tech                             | nical                                  |          |
| animenaca positive effects [  | _                          | 2  | 3  | 4                     | 5  |   |  |                             |                                     |  |          |
| subitem not at all important  | 0                          | 0  | 0  | •                     | 0  | essential   |  |                             |                                     |  |          |
|   |                            |  |  |                       |  |   |  |                             |                                     |  |          |
|   |                            |  |  |                       |  |   |  |                             |                                     |  |          |
| Does your paper address s   | subi                       | tem  | 19-i   | ?                     |  |   |  |                             |                                     |  |          |
|   |                            |  |  |                       |  |   |  |                             |                                     |  |          |
| Copy and paste relevant sections: to indicate direct quotes   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| his" to indicate direct quotes<br>additional information not in   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| his" to indicate direct quotes<br>additional information not in   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes<br>additional information not in<br>for your study   | tions<br>s fro             | fror<br>m yc   | n the  | nanus                 | scrip  | ot), or elabo   | orate oi   | n this ite                  | m by p                              | rovidin                                | g        |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for the state of the state | tions<br>s fro<br>the      | s from   | m the  | nanus                 | scrip<br>expla   | ot), or elaboain why the                              | orate or<br>e item i   | n this ite<br>s not ap      | m by p                              | rovidin                                | g        |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for staff/researchers  | tions s from the           | s from your ms, o  | m the<br>our m<br>or bri                           | manus                 | scrip<br>expla   | ipants or   | observ   | n this ite<br>s not ap      | m by pplicab                        | orovidin<br>e/relev                    | g        |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for staff/researchers Include qualitative feedback available, on strengths and s   | eedli from                 | s from your ms, or ms,  | m the<br>our m<br>or bri                           | m pa<br>ants          | explain a control or of the approximation or of the approximation and the approximation  | ipants or observation oplication, e                   | observate of the control of the cont | rations staff/really if the | m by pplicable  from  search y poin | e/relev<br>e/relev<br>ners, if<br>t to | g<br>ant |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for staff/researchers Include qualitative feedback available, on strengths and sunintended/unexpected effects  | eedle from hortects of     | s from your ms, or ms,  | m the<br>our m<br>or bri                           | m pa<br>ants<br>of th | explained and the second of th | ipants or observation oplication, edes (if available) | observate of the control of the cont | rations staff/really if the | m by pplicable  from  search y poin | e/relev<br>e/relev<br>ners, if<br>t to | g<br>ant |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for staff/researchers Include qualitative feedback available, on strengths and sunintended/unexpected effects  | eedle from hortects con as | s from your ms, of the many of the ms, of th | m the<br>our m<br>or bri<br>ticip<br>ings<br>es. T | m pa<br>ants<br>of th | explained and the decision of the appropriate the decision of the appropriate the decision of the appropriate  | ipants or observation oplication, edes (if available) | observate of the control of the cont | rations staff/really if the | m by pplicable  from  search y poin | e/relev<br>e/relev<br>ners, if<br>t to | g<br>ant |
| this to indicate direct quotes additional information not in for your study  Not applicable.  19-ii) Include qualitative for staff/researchers nclude qualitative feedback  | eedle from hortects of     | s from your ms, of the many of the ms, of th | m the<br>our m<br>or bri                           | m pa<br>ants<br>of th | explained and the second of th | ipants or observation oplication, edes (if available) | observate of the control of the cont | rations staff/really if the | m by pplicable  from  search y poin | e/relev<br>e/relev<br>ners, if<br>t to | g<br>ant |

| DISCUSSION   |                                  |   |   |                                |  |   |    |
|--|----------------------------------|---|---|--------------------------------|--|---|----|
| 22) Interpretation                                     | on                               | CC  | ns  | sist                           | ter  | t with results, balancir  | ıg |
| benefits and ha  | rm                               | ıs,   | ar  | nd (                           | CO   | nsidering other relevan   | t  |
| evidence   |                                  |   |   |                                |  |   |    |
|  |                                  |   |   |                                |  | of the comparator, lack of or partial rs or centers in each group |    |
| 22-i) Restate study questi starting with primary outc  |                                  |   |   |                                |  | the answers suggested by the data, utcomes (use)                  |    |
| Restate study questions and primary outcomes and proce |                                  |   |   |                                |  | ers suggested by the data, starting with                          |    |
|  | 1                                | 2   | 3   | 4                              | 5  |   |    |
| subitem not at all important                           | 0                                | 0   | 0   | 0                              | 0  | essential   |    |
| this" to indicate direct quote                         | tions s fro the urrer omation ta | m yo<br>ms,<br>nt stu<br>ed w<br>arget<br>drink | m the<br>our m<br>or br<br>udy web-b<br>ting a<br>nking<br>ncy, f | e manu iefly was to asec adole | explexed of test of te | eening and its with at-risk  ured by a of binge cantly            |    |
| 22-ii) Highlight unanswere                             | ed n                             | ew c  | ques  | tion                           | s, su  | ggest future research   |    |
| Highlight unanswered new q                             |                                  |   | -   |                                |  |   |    |
| riigiiiigiit ananowerea new q                          | 1                                | 2   | 3   | 4                              | 5  |   |    |
| riigiiigiit ananowerea new q                           |                                  |   |   |                                |  |   |    |
| subitem not at all important                           | 0                                | 0   | $\circ$   | $\circ$                        | •  | essential   |    |

additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Yes, "we found no effect on drug use, which calls for further research on effective intervention models, delivery modes and recruitment strategies." 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 20-i) Typical limitations in ehealth trials Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events. 1 2 3 4 5 subitem not at all important ( ) ( ) ( ) essential Does your paper address subitem 20-i? \* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Yes: "Our study has a number of limitations. First and foremost results are limited by the higher than expected drop-out rate for follow-up assessment, which is a frequent problem in webbased trials [67,71]. Drop-out might be partly caused by invalid email addresses used by the participants and the fact that the system only sent one email reminder per participant [94]. Even though we detected no serious attrition bias this may limit the validity of the study findings. Although in case of large drop any 21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial 21-i) Generalizability to other populations Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

yes: "we consider the realistic setting of this trial a significant strength. In fact, apart from the evaluation requirements at baseline the actual intervention program was equivalent to a potential real world application. We thus feel confident in saying that our study has realistic public health implications."

## 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other cointerventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

|                              | 1 | 2 | 3 | 4 | 5 |           |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "apart from the evaluation requirements at baseline the actual intervention program was equivalent to a potential real world application. We thus feel confident in saying that our study has realistic public health implications."
"However, the incitement by lottery as an incentive for participation may have increased the reach to a higher level than can be expected in implementation outside a research project."

### OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Yes, Trial registration: International Standard Randomised Controlled Trial Registry: ISRCTN95538913 (http://www.isrctn.com/ISRCTN95538913; (Archived by WebCite® at http://www.webcitation.org/6XkuUEwBx).

## 24) Where the full trial protocol can be accessed, if available

#### Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

55. Arnaud N, Bröning S, Drechsel M, Thomasius R, Baldus C. Web-based screening and brief intervention for poly-drug use among teenagers: study protocol of a multicentre two-arm randomized controlled trial. BMC Public Health 2012; 12:826.

# 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "The study was funded by the Drug Prevention and Information Programme of the European Union (Grant agreement no. JUST/2010/DPIP/AG/0914-30-CE-0379823/00-48)."

### X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

| Does your paper address subitem X27-i?   |   |
|--|---|
| Copy and paste relevant sections from the manuscript (inc<br>this" to indicate direct quotes from your manuscript), or el<br>additional information not in the ms, or briefly explain why<br>for your study  | aborate on this item by providing                     |
| Yes: "Competing interests The authors were involved in the development of the intervention."   |   |
|  | ~   |
| A b a c # +b a OONCODT FUEAU TU  |   |
| About the CONSORT EHEALTH  | cnecklist   |
| As a result of using this checklist, did you make char   | nges in your manuscript? *                            |
| yes, major changes   | •   |
| <ul><li>yes, minor changes</li></ul>   |   |
| ∩ no   |   |
|  |   |
|  |   |
| What were the most important changes you made as   | a result of using this checklist?                     |
| What were the most important changes you made as - Changes around the reporting on concept of "blinding" RCTs  |   |
| - Changes around the reporting on concept of "blinding"  |   |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the o   | in  |
|  | in  |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  | in  |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  | checklist INCLUDING making                            |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  | checklist INCLUDING making                            |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  As a result of using this checklist, do you think your in the changes in your manuscript.   | checklist INCLUDING making                            |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  As a result of using this checklist, do you think your in yes   | checklist INCLUDING making                            |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  As a result of using this checklist, do you think your particles of the content of | checklist INCLUDING making manuscript has improved? * |
| - Changes around the reporting on concept of "blinding" RCTs  How much time did you spend on going through the changes in your manuscript *  2 hrs.  As a result of using this checklist, do you think your in yes  o yes  no  | checklist INCLUDING making manuscript has improved? * |

| This is a very use study planning! | eful instrument for guidance on reporting and  |
|------------------------------------|--|
| submit                             | ve this form as PDF before you click   |
| _                                  | ord that you filled in this form, we recommend to generate a PDF of ac, simply select "print" and then select "print as PDF") before you |
| When you submit<br>file.           | your (revised) paper to JMIR, please upload the PDF as supplementary   |
| •                                  | ne text in the textboxes is cut off, as we still have the complete r database. Thank you!  |
| Final step:                        | Click submit!  |
| Click submit so w                  | ve have your answers in our database!  |
| Senden  Geben Sie niemals          | s Passwörter über Google Formulare weiter.   |
|                                    |  |